Prevalence of treatment-resistant depression in primary care: cross-sectional data

Thomas, Laura; Keßler, David; Campbell, John; Morrison, Jill; Peters, Tim J.; Williams, Chris; Lewis, Glyn; Wiles, Nicola

doi:10.3399/bjgp13x675430

Cited by 134 publications

(98 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Novel DBS indications planning: It is likely that DBS will become a bearer of hope for many psychiatric disorders -in particular for depression, OCD and Tourette's syndromefor which known therapies have failed (e.g., recent studies estimate that more than 50% of patients suffering from depression may be treatment-resistant; Thomas et al 2013). …”

Section: Institution Dimensionmentioning

confidence: 99%

Ethical Focal Points in the International Practice of Deep Brain Stimulation

et al. 2014

View full text Add to dashboard Cite

Deep brain stimulation (DBS) is a standard therapy for several movement disorders, and the list of further indications that are investigated is growing rapidly. We performed two surveys among DBS experts (n1D 113) and centers (n2D 135) to identify ethical focal points in the current global practice of DBS. The data indicate a mismatch between the patients' fears and the frequencies of the suspected side effects, a significant "satisfaction gap," signs of improvements of outcome, habituation effects in terms of involved disciplines, a growing spectrum of novel indications that partly conflicts with the experts' success probability ratings, and differences in the density of supply between countries that might affect the future development of DBS. We formulate ethical recommendations with regard both to patient-related practices (e.g., recruitment, assurance of alternatives) and to institutional development (e.g., measures for quality assurance and for the development of novel DBS indications).

show abstract

Section: Institution Dimensionmentioning

confidence: 99%

Ethical Focal Points in the International Practice of Deep Brain Stimulation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Major challenges are that relapse or recurrence rates after remission or recovery remain very high and tend to increase (up to 80%) with the number of episodes (Beshai, Dobson, Bockting, & Quigley, 2011). Moreover, there is a substantial proportion of patients who fail to respond to treatment (Thomas et al, 2013). Treatment-resistant and recurrent depressive episodes are strongly associated with poor psychosocial outcomes due to increasing social problems (e.g., elevated divorce rates) and financial problems (e.g., multiple sick leaves, unemployment).…”

Section: Introductionmentioning

confidence: 99%

Cognitive control interventions for depression: A systematic review of findings from training studies

Koster

Hoorelbeke

Onraedt

et al. 2017

Clinical Psychology Review

212

159

View full text Add to dashboard Cite

There is a strong interest in cognitive control training as a new intervention for depression.Given the recent promising meta-analytical findings regarding the effects of cognitive training on cognitive functioning and depressive symptomatology, the current review provides an indepth discussion of the role of cognitive control in depression. We consider the state-of-theart research on how manipulation of cognitive control may influence cognitive and depression-related outcomes. Evidence for the effectiveness of cognitive control training procedures are discussed in relation to three stages of depression (at-risk, clinically depressed, remission) as well as the training approach that was deployed, after which the putative theoretical mechanisms are discussed. Finally, we provide ways in which cognitive control training can be utilized in future research.COGNITIVE CONTROL TRAINING FOR DEPRESSION 3

show abstract

“…However, because of the limited efficacy, low remission rates (Rush et al 2006), and treatment resistant depression (TRD) (Thomas et al 2013), new treatment strategies are needed (Mihaljevic-Peles et al 2011). Vortioxetine is a recently introduced antidepressant with a novel mechanism of action.…”

Section: Introductionmentioning

confidence: 99%